Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

111 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
TCERG1L allelic variation is associated with cisplatin-induced hearing loss in childhood cancer, a PanCareLIFE study.
Meijer AJM, Diepstraten FA, Langer T, Broer L, Domingo IK, Clemens E, Uitterlinden AG, de Vries ACH, van Grotel M, Vermeij WP, Ozinga RA, Binder H, Byrne J, van Dulmen-den Broeder E, Garrè ML, Grabow D, Kaatsch P, Kaiser M, Kenborg L, Winther JF, Rechnitzer C, Hasle H, Kepak T, Kepakova K, Tissing WJE, van der Kooi ALF, Kremer LCM, Kruseova J, Pluijm SMF, Kuehni CE, van der Pal HJH, Parfitt R, Spix C, Tillmanns A, Deuster D, Matulat P, Calaminus G, Hoetink AE, Elsner S, Gebauer J, Haupt R, Lackner H, Blattmann C, Neggers SJCMM, Rassekh SR, Wright GEB, Brooks B, Nagtegaal AP, Drögemöller BI, Ross CJD, Bhavsar AP, Am Zehnhoff-Dinnesen AG, Carleton BC, Zolk O, van den Heuvel-Eibrink MM; PanCareLIFE Consortium; and the CPNDS Consortium. Meijer AJM, et al. Among authors: rassekh sr. NPJ Precis Oncol. 2021 Jul 14;5(1):64. doi: 10.1038/s41698-021-00178-z. NPJ Precis Oncol. 2021. PMID: 34262104 Free PMC article.
The cumulative incidence of cisplatin-induced hearing loss in young children is higher and develops at an early stage during therapy compared with older children based on 2052 audiological assessments.
Meijer AJM, Li KH, Brooks B, Clemens E, Ross CJ, Rassekh SR, Hoetink AE, van Grotel M, van den Heuvel-Eibrink MM, Carleton BC. Meijer AJM, et al. Among authors: rassekh sr. Cancer. 2022 Jan 1;128(1):169-179. doi: 10.1002/cncr.33848. Epub 2021 Sep 7. Cancer. 2022. PMID: 34490624 Free article.
Genetic markers of cisplatin-induced hearing loss in children.
Carleton BC, Ross CJ, Pussegoda K, Bhavsar AP, Visscher H, Lee JW, Brooks B, Rassekh SR, Dubé MP, Hayden MR. Carleton BC, et al. Among authors: rassekh sr. Clin Pharmacol Ther. 2014 Sep;96(3):296-8. doi: 10.1038/clpt.2014.92. Clin Pharmacol Ther. 2014. PMID: 25141953
Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children.
Visscher H, Ross CJ, Rassekh SR, Sandor GS, Caron HN, van Dalen EC, Kremer LC, van der Pal HJ, Rogers PC, Rieder MJ, Carleton BC, Hayden MR; CPNDS Consortium. Visscher H, et al. Among authors: rassekh sr. Pediatr Blood Cancer. 2013 Aug;60(8):1375-81. doi: 10.1002/pbc.24505. Epub 2013 Feb 25. Pediatr Blood Cancer. 2013. PMID: 23441093 Clinical Trial.
Role of TPMT and COMT genetic variation in cisplatin-induced ototoxicity.
Carleton BC, Ross CJ, Bhavsar AP, Amstutz U, Pussegoda K, Visscher H, Lee JW, Brooks B, Rassekh SR, Dubé MP, Hayden MR. Carleton BC, et al. Among authors: rassekh sr. Clin Pharmacol Ther. 2014 Mar;95(3):253. doi: 10.1038/clpt.2013.219. Epub 2013 Nov 5. Clin Pharmacol Ther. 2014. PMID: 24193170 No abstract available.
Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children.
Visscher H, Ross CJ, Rassekh SR, Barhdadi A, Dubé MP, Al-Saloos H, Sandor GS, Caron HN, van Dalen EC, Kremer LC, van der Pal HJ, Brown AM, Rogers PC, Phillips MS, Rieder MJ, Carleton BC, Hayden MR; Canadian Pharmacogenomics Network for Drug Safety Consortium. Visscher H, et al. Among authors: rassekh sr. J Clin Oncol. 2012 May 1;30(13):1422-8. doi: 10.1200/JCO.2010.34.3467. Epub 2011 Sep 6. J Clin Oncol. 2012. PMID: 21900104
111 results